Do intellectual property rights and data exclusivity encourage innovation in the pharmaceutical world?

Systematic Reviews in Pharmacy

Volumn 1, Issue 2, 2010, Pages 190-193

  Gangil, J ^a   Thunga, G ^a   Nagaich, R ^b  

^a MANIPAL COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^b VNS Institute of Pharmacy   (India)

Author keywords

Data exclusivity; Intellectual property; Patent

Indexed keywords

EID: 84889066503     PISSN: 09758453     EISSN: 09762779     Source Type: Journal    
DOI: 10.4103/0975-8453.75088     Document Type: Review

References (18)

1. Data exclusivity: An Indian perspective. Available from: http://www.ipfrontline.com/depts/article.asp?id=12300. [cited on 2009 Nov 20].
2. Taiwan's data exclusivity protection for pharmaceutical products. Available from: http://www.statusa.gov/mrd_a.nsf/vwNoteIDLookup/NT0003D082/$File/X_6162457.PDF?OpenElement.[citedon2009Nov22].
3. A review of existing data exclusivity legislation in selected countries. Available from: http://www.who.int/intellectualproperty/topics/ip/en/Data.exclusivity.review.doc. [cited on 2009 Nov 22].
4. Data exclusivity: Further protection for pharmaceuticals. Available from: http://www.findlaw.com.au/article/9200.htm. [cited on 2009 Nov 25].
5. Doha declaration: Declaration on the TRIPS agreement and public health 2001. Available from: http://www.worldtradelaw.net/doha/tripshealth.pdf. [cited on 2009 Dec 1].
6. DiMasi J. Hansen R, Grabowski H. The price of innovation: New estimates of drug development costs. J Health Eco 2003;22:151-85. Available from: http://www.cptech.org/ip/health/econ/dimasi2003.pdf. [cited on 2009 Dec 2].
7. Skillington G. The protection of test and other data required by Article 39.3 of the TRIPS agreement. NW J INT'L L BUS 2003;24:1-52. Available from: http://www.law.northwestern.edu/jilb/past_issues/vol24no1.html. [cited on 2009 Dec 4].
8. Satyanarayana K, Srivastava S, Ganguly NK. Data protection issues in India. In J Med R 2006;123:723-6. Available from: http://www.medind.nic.in/iby/t06/i6/ibyt06i6p723.pdf. [cited on 2009 Nov 28].
9. A critical analysis of India's probable data exclusivity/data compensation provisions. Available from: www.healthgap.org/camp/novartis/India.doc. [cited on 2009 Nov 20].
10. New economics research supports 13 to 16 years of data exclusivity for biologics. Available from: http://www.innovation.org/documents/File/ Grabowski_Data_Exclusivity_for_New_Biological_Entities_Overview. pdf. [cited on 2009 Nov 18].
11. Pharma firms set to get data exclusivity. Available from: http://timesofindia.indiatimes.com/NEWS/Business/India-Business/ articleshow/msid168640, curpg-2.cms. [cited on 2009 Nov 21].
12. Global model to give instant patent relief to drug cos. Available from: http://economictimes.indiatimes.com/News/News-By-Industry/Healthcare-Biotech/Pharmac euticals/Global-model-to-give-instant-patent-relief-to-drug-cos/articleshow/4488893.cms. [cited on 2009 Dec 6].
13. Basheer S. India's tryst with TRIPS: The patents (Amendment Act) 2005. J L TECH 2005;22(1):151-85. Available from: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=764066. [cited on 2009 Dec 7].
14. Economic aspects of access to medicines after 2005: Product patent protection and emerging firm strategies in the Indian Pharmaceutical Industry. Available from: https://www.who.int/entity/intellectualproperty/studiesPadmashreeSampathFinal.pdf. [cited on 2009 Nov 20].
15. AIDS drugs threatened. Available from: http://www.nytimes.com/2005/03/05/opinion/05sat3.html. [cited on 2009 Nov 20].
16. India could cut-off Africa's access to affordable AIDS drugs. Available from: http://www.healthgap.org/press_releases/05/030104_HGAP_AA_INDIA_IPR.html. [cited on 2009 Nov 29].
17. Data exclusivity regulations in India. Available from: http://www.bilaterals.org/articleprint.php3?id_article=5425. [cited on 2009 Nov 29].
18. Sharma A. Data exclusivity with regard to clinical data. J L TECH 2007;3:100-2. Available from: http://www.nls.ac.in/students/IJLT/resources/3_Indian_JLandTech_82.pdf. [cited on 2009 Dec 7].